摘要
目的 观察原发性高血压患者血浆组织因子途径、组织因子途径抑制物的变化及用依那普利、特拉唑嗪降压治疗后上述指标的变化。方法 发色底物法、Ⅰ期凝固法检测 1、2级原发性高血压患者 5 5例、正常对照者 2 8例的血浆组织因子 (TF)、组织因子途径抑制物 (TFPI)、FⅦ :C活性。 5 5例高血压患者中 2 7例接受依那普利治疗 ,2 8例接受特拉唑嗪治疗 ,疗程 8周。结果 原发性高血压患者血浆TF、FⅦ :C、TFPI活性明显增高 ,与对照组相比差异有显著性(P <0 0 0 1) ;依那普利和特拉唑嗪治疗 8周后血浆TF、FⅦ :C活性下降 ,与治疗前相比差异有显著性 (P <0 0 0 1) ;两药均不影响TFPI的活性。结论 原发性高血压患者血浆组织因子途径活性增加 。
Objective To observe the changes of tissue factor pathway(TFP) and tissue factor pathway inhibitor(TFPI) in essential hypertension and study the effects of enalapril and terazosin. Methods Chromogenic substrate method and one stage clotting assay were used to examine plasma TF and TFPI and FⅦ activities in 55 hypertensives and 28 normotensives. Enalapril was used in 27 hypertensives and terazosin in 28 hypertensives for 8 weeks. Results Plasma TF and TFPI and FⅦ activities were significantly higher in hypertensives than in controls. Enalapril and terazosin reduce blood pressure, with similar effective response. Both drugs downregulate the activities of plasma TF?FⅦ∶C, while enalapril was superior to terazosin; plasma TFPI activity was of little changes by them. Conclusion Activities of TFP and TFPI are enhanced in essential hypertension. Both enalapril and terazosin decrease blood pressure and attenuate prethrombotic state by downregulating the activity of plasma TF?FⅦ:C.
出处
《高血压杂志》
CSCD
2002年第6期527-530,共4页
Chinese Journal of Hypertension
